The M. D. Anderson Cancer Center Administrative Core Facility will serve as a nexus for this SPORE in Multiple Myeloma as the latter strives to develop novel approaches to the prevention, early detection, diagnosis, staging, and treatment of this hematologic malignancy. This Core's overall goals will be to provide coordination and oversight of SPORE activities, to facilitate internal and external collaborations as well as intramural and extramural communications, and to thereby expedite in every way possible the translational mission ofthe SPORE.
Specific aims of this Core will include: 1. To assure the overall scientific quality and function of all of the SPORE components, including the five Projects, six Cores, and the Developmental Research and Career Development Programs;2. To establish and monitor compliance of SPORE activities with all applicable local, state, national, and international regulations and requirements;3. To oversee SPORE expenditures, and maintain and distribute budget information on a regular basis;4. To organize and convene all necessary SPORE meetings, including those ofthe Internal and External Advisory Boards, utilizing the M. D. Anderson conference and videoconference capabilities, and provide summaries thereof to applicable personnel;5. To assist the SPORE Developmental Research Program and Career Development Program Directors and Co-Directors in administering these vital components;6. To support the preparation of all SPORE publications and other external communications;7. To coordinate, obtain, and maintain Institutional commitments to the SPORE from the participating centers;8. To encourage and facilitate intraand inter-SPORE communications, collaborations, and data and resource sharing;and 9. To promote communications and collaborations with other SPORE partners in both academia and industry. Through these activities, the Administrative Core will help both established and developmental projects clearly focus on their translational goals, and to identify and implement steps required to translate the research to and from the clinic to produce objective evidence of improving clinically relevant endpoints in multiple myeloma.

Public Health Relevance

The Administrative Core Facility will play the central role on this SPORE in helping both established and developmental projects clearly focus on their translational goals, and to identify and implement steps required to translate the research to and from the clinic to produce objective evidence of improving outcomes in multiple myeloma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA142509-03
Application #
8380824
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
3
Fiscal Year
2012
Total Cost
$65,491
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Purushothaman, Anurag; Bandari, Shyam K; Chandrashekar, Darshan S et al. (2017) Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget 8:73723-73732
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Carballo-Zarate, Adrian A; Medeiros, L Jeffrey; Fang, Lianghua et al. (2017) Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol 30:843-853
Xu-Monette, Zijun Y; Zhang, Mingzhi; Li, Jianyong et al. (2017) PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol 8:1597
Wan, Wen; Pei, Xin-Yan; Grant, Steven et al. (2017) Nonlinear response surface in the study of interaction analysis of three combination drugs. Biom J 59:9-24
Yu, Li; Tu, Meifeng; Cortes, Jorge et al. (2017) Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129:1658-1668
Nguyen, Tri; Parker, Rebecca; Hawkins, Elisa et al. (2017) Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget 8:31478-31493
(2017) Correction: Integration of Novel Agents into the Care of Patients with Multiple Myeloma. Clin Cancer Res 23:2605
Lee, Hans C; Wang, Hua; Baladandayuthapani, Veerabhadran et al. (2017) RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol 177:80-94
Manasanch, Elisabet E; Orlowski, Robert Z (2017) Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14:417-433

Showing the most recent 10 out of 190 publications